What it is
We have previously discussed what type of injury that Fournier’s gangrene is, please see the link here. This blog is to clarify the qualifying standard that is currently required due to the August 2018 label change issued by the FDA when they determined that SGLT2 inhibitors could be linked to the Fournier’s gangrene injuries.
As previously stated in our blog, the signature injury in this case is Fournier’s gangrene. Fournier’s gangrene is the necrosis of body tissue, particularly in the genitalia, perineum, or colorectal areas from an infection. It is most commonly associated with the graying or blackening of skin due to the infection area and the type of necrotic tissue. It is extremely dangerous and even fatal if left untreated. Additionally, males are 10 times more likely to develop Fournier’s gangrene than females.
The current standard for qualifying in the Jardiance Fournier’s Gangrene litigation is that (1) a person must’ve been injured after the consumption of Jardiance, and (2) the person that is injured must have begun taking Jardiance prior to the warning label changing in 2018, which would be prior to the August 2018 FDA warning.
Call the Professionals
If you or a loved one have been injured by taking this drug, and you took the drug prior to the label change of August 29, 2018, please give us a call at 888-585-5970. The attorneys here at the Michael Brady Lynch Firm are the best at litigating pharmaceutical drug and device cases.